Alnylam Pharmaceuticals, Inc. - Common Stock (NQ:ALNY)

247.51 -10.49 (-4.07%)

Streaming Delayed Price Updated: 4:00 PM EDT, Sep 10, 2026 Add to My Watchlist

Price and Volume

Volume	1,625,931
Open	256.68
Bid (Size)	245.55 (80)
Ask (Size)	258.00 (40)
Prev. Close	258.00
Today's Range	246.42 - 256.68
52wk Range	197.81 - 495.55
Shares Outstanding	118,847,693
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth in Biotech ↗

September 03, 2026

Via Chartmill

Alnylam to Webcast Presentations at Upcoming September Investor Conferences

September 02, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

Performance

YTD	-38.1%	-38.1%
1 Month	+14.1%	+14.1%
3 Month	-15.0%	-15.0%
6 Month	-22.8%	-22.8%
1 Year	-48.7%	-48.7%

More News

Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings

August 30, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

If You Invested $100 In Alnylam Pharmaceuticals Stock 20 Years Ago, You Would Have This Much Today ↗

August 28, 2026

Via Benzinga

Alnylam Pharmaceuticals (NASDAQ:ALNY): A Value Stock Worthy of Investor Attention ↗

August 20, 2026

Via Chartmill

Alnylam Pharmaceuticals (NASDAQ:ALNY): Affordable Growth at a Reasonable Valuation ↗

August 01, 2026

Via Chartmill

Alnylam Pharmaceuticals, Inc. Investors: Investigation Launched Into Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) by Kessler Topaz Meltzer & Check, LLP

August 24, 2026

Via NewMediaWire

Alnylam to Present New Data Reinforcing Strength in RNAi-Powered TTR Silencing and Continued Progress in Hypertension at ESC Congress 2026

August 24, 2026

From Alnylam Pharmaceuticals, Inc.

Via Business Wire

(NASDAQ: ALNY): Investigation Launched Into Alnylam Pharmaceuticals, Inc. by Kessler Topaz Meltzer & Check, LLP

August 20, 2026

Via NewMediaWire

Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm

August 20, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

ALNY SHAREHOLDER ALERT: Alnylam Pharmaceuticals, Inc. Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

August 19, 2026

From Kirby McInerney LLP

Via Business Wire

NASDAQ: ALNY: Kessler Topaz Meltzer & Check, LLP Launches Investigation Into Alnylam Pharmaceuticals, Inc.

August 19, 2026

Via NewMediaWire

ALNY ALERT: Investigation Launched Into Alnylam Pharmaceuticals, Inc., Investors Are Encouraged to Contact KTMC Law Firm

August 18, 2026

Via NewMediaWire

ALNY Investor Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

August 17, 2026

Via NewMediaWire

Why the Alnylam Sell-Off Looks Overdone -- and What Investors Are Missing ↗

August 16, 2026

Via The Motley Fool

NASDAQ: ALNY Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) Investors to Contact the Firm

August 14, 2026

From Kessler Topaz Meltzer & Check, LLP

Via Business Wire

$1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today ↗

August 10, 2026

Via Benzinga

ALNYLAM INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. is Investigating Alnylam Pharmaceuticals, Inc. on Behalf of Alnylam Stockholders and Encourages Investors to Contact the Firm

August 04, 2026

From Bragar Eagel & Squire

Via GlobeNewswire

Alnylam (ALNY) Q2 2026 Earnings Call Transcript ↗

August 03, 2026

Via The Motley Fool

ALNY Investors Have Opportunity to Join Alnylam Pharmaceuticals, Inc. Fraud Investigation with SBS Law

August 03, 2026

From Schall, Brown & Schwartz LLP

Via Business Wire

Alnylam Pharma (ALNY) Q2 2026 Earnings Call Transcript ↗

July 30, 2026

Via The Motley Fool

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm

July 30, 2026

From Glancy Prongay Wolke & Rotter LLP

Via Business Wire

Alnylam Pharmaceuticals, Inc. (ALNY) Shareholders Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

July 30, 2026

From Law Offices of Howard G. Smith

Via Business Wire

Securities Fraud Investigation Into Alnylam Pharmaceuticals, Inc. (ALNY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

July 30, 2026

From The Law Offices of Frank R. Cruz

Via Business Wire

Here are the top movers in Thursday's session. ↗

July 30, 2026

Via Chartmill

Frequently Asked Questions

Is Alnylam Pharmaceuticals, Inc. - Common Stock publicly traded?

Yes, Alnylam Pharmaceuticals, Inc. - Common Stock is publicly traded.

What exchange does Alnylam Pharmaceuticals, Inc. - Common Stock trade on?

Alnylam Pharmaceuticals, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock?

The ticker symbol for Alnylam Pharmaceuticals, Inc. - Common Stock is ALNY on the Nasdaq Stock Market

What is the current price of Alnylam Pharmaceuticals, Inc. - Common Stock?

The current price of Alnylam Pharmaceuticals, Inc. - Common Stock is 247.51

When was Alnylam Pharmaceuticals, Inc. - Common Stock last traded?

The last trade of Alnylam Pharmaceuticals, Inc. - Common Stock was at 09/10/26 04:00 PM ET

What is the market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock?

The market capitalization of Alnylam Pharmaceuticals, Inc. - Common Stock is 29.42B

How many shares of Alnylam Pharmaceuticals, Inc. - Common Stock are outstanding?

Alnylam Pharmaceuticals, Inc. - Common Stock has 29B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.